MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NF κB-TNFα Pathway

The incidence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 20-45% in the general population of Western countries.[1,2] Although NAFLD carries a relatively benign prognosis, a significant proportion of patients can progress to NASH and later cirrhosis with the risk of developing hepatocellular carcinoma (HCC).[3,4] It is estimated that NASH-related HCC accounts for ≥ 13% of cases in the US.[5–7] Although the progression of hepatosteatosis to NASH has been studied extensively, the precise mechanism(s) is still under intense investigation.

Source: Journal of Hepatology - September 12, 2018 Category: Gastroenterology Authors: Tianpeng Zhang, Junjie Hu, Xiaomei Wang, Xiaoling Zhao, Zhuoyu Li, Junqi Niu, Clifford J. Steer, Guohua Zheng, Guisheng Song Source Type: research